Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Leases (2019 - 2025)

Historic Operating Leases for Zevra Therapeutics (ZVRA) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • Zevra Therapeutics' Operating Leases rose 19130.43% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 19130.43%. This contributed to the annual value of $792000.0 for FY2024, which is 7368.42% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Operating Leases stood at $1.4 million, which was up 19130.43% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Operating Leases registered a high of $1.8 million during Q2 2021, and its lowest value of $456000.0 during Q4 2023.
  • Moreover, its 5-year median value for Operating Leases was $1.1 million (2022), whereas its average is $1.1 million.
  • Per our database at Business Quant, Zevra Therapeutics' Operating Leases plummeted by 6553.29% in 2023 and then surged by 19130.43% in 2025.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Operating Leases stood at $1.6 million in 2021, then dropped by 16.69% to $1.3 million in 2022, then crashed by 65.53% to $456000.0 in 2023, then soared by 73.68% to $792000.0 in 2024, then surged by 77.65% to $1.4 million in 2025.
  • Its Operating Leases was $1.4 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.2 million in Q1 2025.